The pathogenesis of multiple sclerosis: Relating human pathology to experimental studies

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 4, 2006, Pages 305-318

  Ludwin, Samuel K ^a,b  

^a Queens University of Charlotte   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Autoimmunity; Demyelination; Multiple sclerosis; Remyelination

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CYTOKINE; ETHIDIUM BROMIDE; GADOLINIUM; GAMMA INTERFERON; GELATINASE B; GLATIRAMER; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN 70; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MYELIN ASSOCIATED GLYCOPROTEIN; NATALIZUMAB; POTASSIUM ION; SODIUM CHANNEL; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR; TYROSINE KINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN RECOGNITION; ASTROCYTE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOACCUMULATION; BRAIN BIOPSY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EXAMINATION; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DEMYELINATION; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA MICROARRAY; DRUG RESPONSE; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTAL STUDY; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; GLIOSIS; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; ISCHEMIA; MACROPHAGE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVE BIOPSY; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INJURY; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PELIZAEUS MERZBACHER DISEASE; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; SPINAL CORD ATROPHY; STROKE; SYMPTOMATOLOGY; TH1 CELL; TH2 CELL; WHITE MATTER; ANIMAL; CENTRAL NERVOUS SYSTEM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM; HUMANS; MULTIPLE SCLEROSIS;

EID: 33744966338     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000225024.12074.80     Document Type: Review

References (76)

1. Prat A, Antel J. Pathogenesis of multiple sclerosis. Curr Opin Neurol 2005;18:225-30
2. Hafler D, Slavic JM, Anderson DE, et al. Multiple sclerosis. Immunol Rev 2005;204:208-31
3. Willer CJ, Dyment DA, Sadovnick AD, et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003;100:12877-82
4. Ebers GC, Sadovnick AD, Dyment DA, et al. A parent of origin effect in multiple sclerosis: Observations in half siblings. Lancet 2004;363:857-60
5. Van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. Br Med J 2003;327:316
6. Ponsonby AL, Lucas RM, Van der Mei IA. A potential role for UVR and vitamin D in the induction of MS, type 1 diabetes, rheumatoid arthritis. Photochem Photobiol 2005;81:1267-75
7. Lincoln MB, Montpetit A, Cader MZ, et al. A predominant role for the HLA class 11 region in the association of the MHC region with multiple sclerosis. Nat Genet 2005;37:1108-12
8. Dyment DA, Sadovnick AD, Willer CJ, et al. An extended genome scan in 442 Canadian multiple sclerosis-affected sibships a report form the Canadian Collaborative Study Group. Hum Mol Genet 2004;13:1005-15
9. Ludwin SK. Neuropathology of multiple sclerosis. Neuroimag Clin N Am 2000;10:625-48, vii
10. Lucchinetti CF, Parisi J, Bruck W. The pathology of multiple sclerosis. Neurol Clin 2005;23:77-105, vi
11. Charcot JM. Histologie de la sclerose en plaque. Gazette Hopital (Paris) 1868;41:554-66
12. Ludwin SK, Henry JM, McFarland H. Vascular proliferation and angiogenesis in multiple sclerosis: Clinical and pathogenetic implications. (Abstract) J Neuropathol Exp Neurol 2001;60:505
13. Whitney LW, Ludwin SK, Mcfarland HF, et al. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Immunol 2001;121:40-48
14. Mycko MP, Papoian R, Boschert U, et al. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin Neurol Neurosurg 2004;106:223-29
15. Ludwin SK. Pathogenic classification systems in MS: What is their significance? Mult Scler 2005;11:106-107
16. Van der Valk P, De Groot CJ. Staging of multiple sclerosis (MS) lesions: Pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000;26:2-10
17. Bruck W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788-96
18. Bar-Or A. Immunology of multiple sclerosis. Neurol Clin 2005;23:149-75, vii
19. Kalkers NF, Ameziane N, Bot JCJ, et al. Longitudinal brain volume measurement in multiple sclerosis: Rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002;59:1572-76
20. Markovic-Plese S, Pinilla C, Martin R. The initiation of the autoimmune response in multiple sclerosis. Clin Neurol Neurosurg 2004;106:218-22
21. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291-301
22. Chaudhuri A, Behan PO. Multiple sclerosis is not an autoimmune disease. Arch Neurol 2004;61:1610-12
23. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004;611:613-15
24. Kleine TO, Zwerenz P, Graser C, et al. Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8. Brain Res Bull 2003;61:327-46
25. Quandt JA, Baig M, Yao K, et al. Unique clinical and pathological findings in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice. J Exp Med 2004;200:223-34
26. Lucchinetti C, Bruck W, Parisi J, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999;122:2279-95
27. Bruck W, Stadelmann C. The spectrum of multiple sclerosis: New lessons from pathology. Curr Opin Neurol 2005;18:221-24
28. Ruffini F, Kennedy TE, Antel J. Inflammation and remyelination in the central nervous system: A tale of two systems. Am J Pathol 2004;164:1519-22
29. Kuhlmann T, Lucchinetti C, Zettl UK, et al. Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. Glia 1999;28:34-39
30. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004;55:458-68
31. Ludwin SK, Johnson ES. Evidence for a "Dying-Back7" gliopathy in demyelinating disease. Ann Neurol 1981;9:301-05
32. Rodriguez M, Scheithauer BW, Forbes G, et al. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993;68:627-36
33. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17
34. Moscarello MA, Mak B, Nguyen TA, et al. Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination. Mult Scler 2002;8:130-38
35. Kornek B, Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res Bull 2003;61:321-26
36. Aboul-Enein F, Rauschka H, Kornek B, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003;62:25-33
37. Lucchinetti C. Update on the international project on pathological correlates in MS. Mult Scler 2004;11:99-100
38. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579-82
39. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transections in the lesions of multiple sclerosis. New Engl J Med 1998;338:278-85
40. Bruck W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult Scler 2002;8:93-97
41. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-88
42. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747-54
43. Peterson JW, Trapp BD. Neuropathobiology of multiple sclerosis. Neurol Clin 2005;23:107-29, vi-vii
44. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-12
45. Stys PK. Axonal degeneration in multiple sclerosis: Is it time for neuroprotective strategies? Ann Neurol 2004;55:601-3
46. Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlatation with demyelination and inflammation. Brain 2000;123:1174-83
47. Bruck W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci 2003;Suppl 5:S265-67
48. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: Consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165-71
49. Grigoriadis N, Ben-Hur T, Karussis D, et al. Axonal damage in multiple sclerosis: A complex issue in a complex disease. Clin Neurol Neurosurg 2004;106:211-17
50. Bo L, Nyland H, Trapp BD, et al. Cortical demyelination in multiple sclerosis. (Abstract) J Neuropathol Exp Neurol 2000;59:431
51. Bo L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323-31
52. Dehmeshki J, Chard DT, Leary SM, et al. The normal appearing grey matter in primary progressive multiple sclerosis: A magnetisation transfer imaging study. J Neurol 2003;250:67-74
53. Wood DD, Bilbao JM, O'Connors P, et al. Acute multiple sclerosis (Marburg's type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996;40:18-24
54. de Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002;59:1565-71
55. Evangelou N, Konz D, Esiri MM, et al. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001;124:1813-20
56. Raine CS. Multiple sclerosis: Prospects for remyelination. Mult Scler 1996;2:195-97
57. Bruck W, Kuhlmann T, Stadelmann C. Remyelination in multiple sclerosis. J Neurol Sci 2003;206:181-85
58. Johnson ES, Ludwin SK. The demonstration of recurrent demyelination and remyelination of axons in the central nervous system. Acta Neuropathol (Berl) 1981;53:93-98
59. Ludwin SK, Bakker DA. Can oligodendrocytes attached to myelin proliferate. J Neurosci 1988;8:1239-44
60. Arnett HA, Fancy SP, Alberta JA, et al. bHLH transcripton factor Oligo1 is required to repair demyelinated lesions in the CNS. Science 2004;306:2111-15
61. John GR, Shankar SL, Shafit-Zagardo B, et al. Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nature Med 2002;8:1115-21
62. Satoh J, Onoue H, Arima K, et al. Nogo-A and nogo receptor expresson in demyelinating lesions of multiple sclerosis. J Neuropathol Exp Neurol 2005;64:129-38
63. Althaus H-H. Remyelination in multiple sclerosis: A new role for neurtrophins? Prog Brain Res 2004;146:415-32
64. Bieber AJ, Rodrigues M. Efficient central nervous system remyelination requires T cells. Ann Neurol 2003;53:680-84
65. Stadelmann C, Bruck W. Lessons from the neuropathology of atypical forms of multiple sclerosis. Neurol Sci 2004;Suppl 4:S319-22
66. Moore GRW, Neumann PE, Suzuki K, et al. Balo's concentric sclerosis: New observations on lesion development. Ann Neurol 1985;17:604-11
67. Stadelmann C, Ludwin SK, Tabira T, et al. Tissue conditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005;128:979-87
68. Stadelmann C, Kerschensteiner M, Misgeld T, et al. BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells? Brain 2002;125:75-85
69. De Keyser J, Zeinstra E, Frohman E. Are astrocytes central players in the pathophysiology of multiple sclerosis? Arch Neurol 2003;60:132-36
70. Ludwin SK. Oligodendrocytes from optic nerves subjected to long term Wallerian degeneration retain the capacity to myelinate. Acta Neuropathol (Berl) 1992;84:530-37
71. Bakker DA, Ludwin SK. Blood-brain barrier permeability during cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. J Neurol Sci 1987;78:125-37
72. Lazeron RH, Boringa JB, Schouten M, et al. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Mult Scler 2005;11:524-31
73. Lycklama a Nijeholt GJ, Barkhof F. Differences between subgroups of MS: MRI findings and correlation with histopathology. J Neurol Sci 2003;206:173-74
74. Geurts JJ, Bo L, Pouwels PJ, et al. Cortical lesions in multiple sclerosis: Combined postmortem MR imaging and histopathology. Am J Neuroradiol 2005;26:572-77
75. Barkhof F, McKinstry RC. Quantifying spinal cord demyelination with magnetic transfer imaging. Neurology 2005;64:1677-78
76. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: Magnetic resonance image appearance. Arch Neurol 2003;60:1073-81